



CYTH.002DVI

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


Applicant : Fraser et al.  
Appl. No. : 10/614,431  
Filed : July 7, 2003  
For : SYSTEMS AND METHODS FOR  
TREATING PATIENTS WITH  
PROCESSED LIPOASPIRATE  
CELLS  
Examiner : Lankford Jr., Leon B  
Group Art Unit : 1651

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 29, 2006

(Date)

  
Eric S. Forman, Ph.D., Reg. No. 45,664

**INTERVIEW SUMMARY**

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The attached interview summary reflects the substance of the personal interview held between Examiner Lankford and the undersigned on September 13, 2006.

Appl. No. : 10/614,431  
Filed : July 7, 2003


### SUMMARY OF INTERVIEW

Applicants wish to thank Examiner Lankford for the courtesy extended during the personal interview held on September 13, 2006 and the helpful comments made therein. During the interview between the undersigned and Examiner Lankford, the indefiniteness rejections 35 U.S.C. § 112, second paragraph, the utility rejections raised under 35 U.S.C. §§ 101, the enablement rejections raised under 35 U.S.C. § 112, first paragraph, and the written description rejections under 35 U.S.C. § 112, first paragraph, raised in the Office Action mailed March 30, 2006 were discussed. The undersigned and the Examiner also discussed proposed claim amendments. The undersigned and the Examiner agreed that a proposed claim directed to a method of processing a cell population that comprises adipose stem cells for reintroduction into a patient, comprising removing adipose tissue that comprises adipose stem cells from said patient; introducing the removed adipose tissue into a self-contained cell processing unit configured to maintain a closed pathway; separating said cell population that comprises said adipose stem cells from non-adipose tissue present in the tissue that was removed from said patient within said self-contained cell processing unit while maintaining said closed pathway; concentrating said cell population that comprises adipose stem cells with said self-contained cell processing unit while maintaining said closed pathway; reintroducing said concentrated cell population that comprises concentrated adipose stem cells from said self-contained cell processing unit into said patient; and providing said patient an additional therapeutic agent, would likely overcome the rejections of record.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: September 29, 2006

By:   
Eric S. Furman  
Registration No. 45,664  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550